About allarity therapeutics - ALLR
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The company is focused on development of stenoparib, a novel PARP and tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity Therapeutics was founded by Steen Knudsen and Thomas H. Jensen in 2004 and is headquartered in Tarpon Springs, FL.
ALLR At a Glance
Allarity Therapeutics, Inc.
123 East Tarpon Avenue
Tarpon Springs, Florida 34689
| Phone | 1-401-426-4664 | Revenue | 320.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -11,231,000.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALLR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 48.529 |
| Price to Book Ratio | 1.767 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.166 |
| Enterprise Value to Sales | 7.007 |
| Total Debt to Enterprise Value | 0.624 |
ALLR Efficiency
| Revenue/Employee | 40,000.00 |
| Income Per Employee | -1,403,875.00 |
| Receivables Turnover | 0.358 |
| Total Asset Turnover | 0.016 |
ALLR Liquidity
| Current Ratio | 2.127 |
| Quick Ratio | 2.127 |
| Cash Ratio | 1.742 |
ALLR Profitability
| Gross Margin | 104.063 |
| Operating Margin | -4,220.313 |
| Pretax Margin | -3,790.938 |
| Net Margin | -3,509.687 |
| Return on Assets | -54.909 |
| Return on Equity | -103.803 |
| Return on Total Capital | -100.027 |
| Return on Invested Capital | -103.803 |
ALLR Capital Structure
| Total Debt to Total Equity | 14.245 |
| Total Debt to Total Capital | 12.469 |
| Total Debt to Total Assets | 7.668 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |